Skip to content
Company Analysis

Anika Therapeutics Inc. ANIK

A comprehensive view of key metrics, scores, and financial health for Anika Therapeutics Inc.

Overview of Anika Therapeutics, Inc.

ANIK NMS
Healthcare Drug Manufacturers - Specialty & Generic Micro Cap
Anika Therapeutics, Inc. (ANIK), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $14.20, about 16.3% undervalued vs fair value, -11.9% 1Y return, ranked 418/1110 in sector.
$14.20
-0.70%
As of March 13, 2026
Previous close • Vol 90d: 43.9%
52-Week Range
Market Cap
$204.78M
Enterprise Value
$171.30M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Anika Therapeutics Inc..

Top Beats

Quick Facts

Website https://www.anika.com
HQ Bedford, MA
Employees 288
Fiscal year Dec 31

Next Events

Earnings May 8 Estimated

Fair Value Snapshot

Bear Base Bull
$15
$17
$18
Current: $14.20 +16% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$119.9M
-0.7%%
Gross Profit
$76.0M
-7.9%%
R&D Expense
$25.5M
17.4%%
Operating Income (EBIT)
$-5.1M
-704.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
21.3%
Good

R&D intensity in normal pharma range (15-25%)

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$11.2M

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
8
Active Leaks
4/8
Improving
0
High Impact
8
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Anika Therapeutics Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
61
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
62
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing ANIK's balance between Growth (24.0%), Profitability (35.7%), and Safety (40.3%). Growth 24% Safety 40% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

33th percentile vs peers
34
Key Signals
EPS Growth YoY 32.1% 51p Rev Growth YoY -0.7% 31p Revenue CAGR 3Y -6.7% 25p TSR -60.0% 27p
Strengths
  • Current Ratio in top 20% of peers (4.88, 89th percentile)
  • Quick Ratio in top 20% of peers (3.85, 86th percentile)
  • Strong liquidity position vs peers
Risks
  • Growth below peer median (percentile: 33)

Profitability

49th percentile vs peers
50
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

56th percentile vs peers
56
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Anika Therapeutics Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$16.51
- - -
+16.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info